TY - JOUR AU - Schlessinger, J. PY - 2002 DA - 2002// TI - Ligand-induced, receptor-mediated dimerization and activation of EGF receptor JO - Cell VL - 110 UR - https://doi.org/10.1016/S0092-8674(02)00966-2 DO - 10.1016/S0092-8674(02)00966-2 ID - Schlessinger2002 ER - TY - JOUR AU - Atalay, G. AU - Cardoso, F. AU - Awada, A. AU - Piccart, M. J. PY - 2003 DA - 2003// TI - Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer JO - Ann Oncol VL - 14 UR - https://doi.org/10.1093/annonc/mdg365 DO - 10.1093/annonc/mdg365 ID - Atalay2003 ER - TY - JOUR AU - Klijn, J. G. AU - Berns, P. M. AU - Schmitz, P. I. AU - Foekens, J. A. PY - 1992 DA - 1992// TI - The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients JO - Endocr Rev VL - 13 ID - Klijn1992 ER - TY - JOUR AU - Tsutsui, S. AU - Ohno, S. AU - Murakami, S. AU - Hachitanda, Y. AU - Oda, S. PY - 2002 DA - 2002// TI - Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer JO - Breast Cancer Res Treat VL - 71 UR - https://doi.org/10.1023/A:1013397232011 DO - 10.1023/A:1013397232011 ID - Tsutsui2002 ER - TY - JOUR AU - Witton, C. J. AU - Reeves, J. R. AU - Going, J. J. AU - Cooke, T. G. AU - Bartlett, J. M. PY - 2003 DA - 2003// TI - Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer JO - J Pathol VL - 200 UR - https://doi.org/10.1002/path.1370 DO - 10.1002/path.1370 ID - Witton2003 ER - TY - JOUR AU - Moscatello, D. K. AU - Holgado-Madruga, M. AU - Godwin, A. K. AU - Ramirez, G. AU - Gunn, G. AU - Zoltick, P. W. AU - Biegel, J. A. AU - Hayes, R. L. AU - Wong, A. J. PY - 1995 DA - 1995// TI - Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors JO - Cancer Res VL - 55 ID - Moscatello1995 ER - TY - JOUR AU - Matsui, Y. AU - Halter, S. A. AU - Holt, J. T. AU - Hogan, B. L. AU - Coffey, R. J. PY - 1990 DA - 1990// TI - Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice JO - Cell VL - 61 UR - https://doi.org/10.1016/0092-8674(90)90077-R DO - 10.1016/0092-8674(90)90077-R ID - Matsui1990 ER - TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Cobleigh, M. A. AU - Vogel, C. L. AU - Tripathy, D. AU - Robert, N. J. AU - Scholl, S. AU - Fehrenbacher, L. AU - Wolter, J. M. AU - Paton, V. AU - Shak, S. AU - Lieberman, G. PY - 1999 DA - 1999// TI - Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.9.2639 DO - 10.1200/JCO.1999.17.9.2639 ID - Cobleigh1999 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Burstein, H. J. AU - Harris, L. N. AU - Marcom, P. K. AU - Lambert-Falls, R. AU - Havlin, K. AU - Overmoyer, B. AU - Friedlander, R. J. AU - Gargiulo, J. AU - Strenger, R. AU - Vogel, C. L. PY - 2003 DA - 2003// TI - Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithms JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.02.018 DO - 10.1200/JCO.2003.02.018 ID - Burstein2003 ER - TY - JOUR AU - Travis, A. AU - Pinder, S. E. AU - Robertson, J. F. AU - Bell, J. A. AU - Wencyk, P. AU - Gullick, W. J. AU - Nicholson, R. I. AU - Poller, D. N. AU - Blamey, R. W. AU - Elston, C. W. PY - 1996 DA - 1996// TI - C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators JO - Br J Cancer VL - 74 UR - https://doi.org/10.1038/bjc.1996.342 DO - 10.1038/bjc.1996.342 ID - Travis1996 ER - TY - JOUR AU - Soltoff, S. P. AU - Carraway, K. L. I. I. I. AU - Prigent, S. A. AU - Gullick, W. G. AU - Cantley, L. C. PY - 1994 DA - 1994// TI - ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor JO - Mol Cell Biol VL - 14 UR - https://doi.org/10.1128/MCB.14.6.3550 DO - 10.1128/MCB.14.6.3550 ID - Soltoff1994 ER - TY - JOUR AU - Sartor, C. I. AU - Zhou, H. AU - Kozlowska, E. AU - Guttridge, K. AU - Kawata, E. AU - Caskey, L. AU - Harrelson, J. AU - Hynes, N. AU - Ethier, S. AU - Calvo, B. PY - 2001 DA - 2001// TI - HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cell JO - Mol Cell Biol VL - 21 UR - https://doi.org/10.1128/MCB.21.13.4265-4275.2001 DO - 10.1128/MCB.21.13.4265-4275.2001 ID - Sartor2001 ER - TY - JOUR AU - Tovey, S. M. AU - Witton, C. J. AU - Bartlett, J. M. AU - Stanton, P. D. AU - Reeves, J. R. AU - Cooke, T. G. PY - 2004 DA - 2004// TI - Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labeling JO - Breast Cancer Res VL - 6 UR - https://doi.org/10.1186/bcr783 DO - 10.1186/bcr783 ID - Tovey2004 ER - TY - JOUR AU - Allen, L. F. AU - Lenehan, P. F. AU - Eiseman, I. A. AU - Elliott, W. L. AU - Fry, D. W. PY - 2002 DA - 2002// TI - Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer JO - Semin Oncol VL - Suppl 11 UR - https://doi.org/10.1053/sonc.2002.34049 DO - 10.1053/sonc.2002.34049 ID - Allen2002 ER - TY - JOUR AU - Xia, W. AU - Liu, L. -. H. AU - Ho, P. AU - Spector, N. L. PY - 2004 DA - 2004// TI - Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207166 DO - 10.1038/sj.onc.1207166 ID - Xia2004 ER - TY - JOUR AU - Cohen, M. H. AU - Williams, G. A. AU - Sridhara, R. AU - Chen, G. AU - Pazdur, R. PY - 2003 DA - 2003// TI - FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets JO - Oncologist VL - 8 UR - https://doi.org/10.1634/theoncologist.8-4-303 DO - 10.1634/theoncologist.8-4-303 ID - Cohen2003 ER - TY - JOUR AU - Albain, K. AU - Elledge, R. AU - Gradishar, W. J. AU - Hayes, D. F. AU - Rowinsky, E. AU - Hudis, C. AU - Pusztai, L. AU - Tripathy, D. AU - Modi, S. AU - Rubi, S. PY - 2002 DA - 2002// TI - Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer [abstract 20] JO - Breast Cancer Res Treat VL - 76 ID - Albain2002 ER - TY - JOUR AU - Robertson, J. F. R. AU - Gutteridge, E. AU - Cheung, K. L. AU - Owers, R. AU - Koehler, M. AU - Hamilton, L. AU - Gee, J. AU - Nicholson, R. I. PY - 2003 DA - 2003// TI - Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study [abstract 23] JO - Proc Am Soc Clin Oncol VL - 22 ID - Robertson2003 ER - TY - JOUR AU - Baselga, J. AU - Albanell, J. AU - Ruiz, A. AU - Lluch, A. AU - Gascon, P. AU - Gonzalez, S. AU - Guillen, V. AU - Sauleda, S. AU - Averbuch, S. AU - Rojo, F. PY - 2003 DA - 2003// TI - Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer [abstract 24] JO - Proc Am Soc Clin Oncol VL - 22 ID - Baselga2003 ER - TY - JOUR AU - Winer, E. AU - Cobleigh, M. AU - Dickler, M. AU - Miller, K. AU - Fehrenbacher, L. AU - Jones, C. AU - Justice, R. PY - 2002 DA - 2002// TI - Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer [abstract 445] JO - Breast Cancer Res Treat VL - 76 ID - Winer2002 ER - TY - JOUR AU - Tan, A. R. AU - Yang, X. AU - Berman, A. AU - Lepper, E. R. AU - Cox, M. C. AU - Parr, A. L. AU - Hewitt, S. M. AU - Steinberg, S. M. AU - Lipkowitz, S. AU - Swain, S. M. PY - 2003 DA - 2003// TI - Evaluation of epidermal growth factor receptor signaling in tumor and skin biopsies after treatment with OSI-774 in patients with metastatic breast cancer [abstract 784] JO - Proc Am Soc Clin Oncol VL - 22 ID - Tan2003 ER - TY - JOUR AU - Hidalgo, M. AU - Erlichman, C. AU - Rowinsky, E. K. AU - Koepp-Norris, J. AU - Jensen, K. AU - Boni, J. AU - Korth-Bradley, J. AU - Quinn, S. AU - Zacharchuk, C. PY - 2002 DA - 2002// TI - Phase I trial of EKB0569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors [abstract 65] JO - Proc Am Soc Clin Oncol VL - 21 ID - Hidalgo2002 ER - TY - JOUR AU - Dees, E. C. AU - Burris, H. AU - Hurwitz, H. AU - Dowlati, A. AU - Smith, D. AU - Koch, K. AU - Stead, A. AU - Mangum, S. AU - Harris, J. AU - Spector, N. PY - 2004 DA - 2004// TI - Clinical summary of 67 heavily pre-treated patients with metastatic breast carcinomas treated with GW572016 in a phase Ib study [abstract 3188] JO - Proc Am Soc Clin Oncol VL - 23 ID - Dees2004 ER - TY - JOUR AU - Murren, J. R. AU - Papadimitrakopoulou, V. A. AU - Sizer, K. C. AU - Vaidyanathan, S. AU - Ravera, C. AU - Abbruzzese, J. L. PY - 2002 DA - 2002// TI - A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers [abstract 377] JO - Proc Am Soc Clin Oncol VL - 21 ID - Murren2002 ER - TY - JOUR AU - Blackwell, K. L. AU - Kaplan, E. H. AU - Franco, S. X. AU - Marcom, P. K. AU - Maleski, J. E. AU - Sorensen, M. J. AU - Berger, M. S. PY - 2004 DA - 2004// TI - A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract 3006] JO - Proc Am Soc Clin Oncol VL - 23 ID - Blackwell2004 ER - TY - JOUR AU - Nemunaitis, J. J. AU - Eiseman, I. AU - Cunningham, C. AU - Lenehan, P. AU - Olson, S. AU - Bycott, P. AU - Schlict, M. AU - Zentgraff, R. AU - Shin, D. AU - Zinner, R. PY - 2003 DA - 2003// TI - A phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors [abstract 974] JO - Proc Am Soc Clin Oncol VL - 22 ID - Nemunaitis2003 ER - TY - JOUR AU - Zinner, R. G. AU - Donato, N. J. AU - Nemunaitis, J. J. AU - Cunningham, C. C. AU - Shin, H. J. AU - Zentgraf, R. E. AU - Ayers, G. D. AU - Glisson, B. S. AU - Khuri, F. R. AU - Kies, M. S. PY - 2002 DA - 2002// TI - Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033 [abstract 58] JO - Proc Am Soc Clin Oncol VL - 21 ID - Zinner2002 ER - TY - JOUR AU - Garrison, M. A. AU - Tolcher, A. AU - McCreery, H. AU - Rowinsky, E. K. AU - Schott, A. AU - Mace, J. AU - Drengler, R. AU - Patnaik, A. AU - Denis, L. AU - Lenehan, P. PY - 2001 DA - 2001// TI - A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors [abstract 283] JO - Proc Am Soc Clin Oncol VL - 20 ID - Garrison2001 ER - TY - JOUR AU - Paez, J. G. AU - Janne, P. A. AU - Lee, J. C. AU - Tracy, S. AU - Greulich, H. AU - Gabriel, S. AU - Herman, P. AU - Kaye, F. J. AU - Lindeman, N. AU - Boggon, T. J. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefi-tinib therapy JO - Science VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. AU - Harris, P. L. AU - Haserlat, S. M. AU - Supko, J. G. AU - Haluska, F. G. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Bacus, S. S. AU - Beresford, P. J. AU - Yarden, Y. AU - Spector, N. AU - Smith, B. PY - 2003 DA - 2003// TI - The use of predicting factors and surrogate markers in patients' cancer biopsies treated with targeted antibodies to erbB receptors and erbB tyrosine kinase inhibitors [abstract 3408] JO - Proc Am Soc Clin Oncol VL - 22 ID - Bacus2003 ER - TY - JOUR AU - Mendelsohn, J. AU - Baselga, J. PY - 2003 DA - 2003// TI - Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.01.504 DO - 10.1200/JCO.2003.01.504 ID - Mendelsohn2003 ER - TY - JOUR AU - Saltz, L. B. AU - Meropol, N. J. AU - Loehrer, P. J. AU - Needle, M. N. AU - Kopit, J. AU - Mayer, R. J. PY - 2004 DA - 2004// TI - Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.10.182 DO - 10.1200/JCO.2004.10.182 ID - Saltz2004 ER - TY - JOUR AU - Cunningham, D. AU - Humblet, Y. AU - Siena, S. AU - Khayat, D. AU - Bleiberg, H. AU - Santoro, A. AU - Bets, D. AU - Mueser, M. AU - Harstrick, A. AU - Van Cutsem, E. PY - 2003 DA - 2003// TI - Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract 1012] JO - Proc Am Soc Clin Oncol VL - 22 ID - Cunningham2003 ER - TY - JOUR AU - Johnston, S. R. AU - Head, J. AU - Pancholi, S. AU - Detre, S. AU - Martin, L. A. AU - Smith, I. E. AU - Dowsett, M. PY - 2003 DA - 2003// TI - Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer JO - Clin Cancer Res VL - 9 ID - Johnston2003 ER - TY - JOUR AU - Massarweh, S. AU - Shou, J. AU - Mohsin, S. K. PY - 2002 DA - 2002// TI - Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors [abstract 130] JO - Proc Am Soc Clin Oncol VL - 21 ID - Massarweh2002 ER - TY - JOUR AU - May, B. B. Y. AU - Bristow, R. B. AU - Kim, J. AU - Siu, L. L. PY - 2003 DA - 2003// TI - Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.10.044 DO - 10.1200/JCO.2003.10.044 ID - May2003 ER - TY - JOUR AU - Lu, C. AU - Speers, C. AU - Zhang, Y. AU - Xu, X. AU - Hill, J. AU - Steinbis, E. AU - Celestino, J. AU - Shen, Q. AU - Kim, H. AU - Hilsenbeck, S. PY - 2003 DA - 2003// TI - Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors JO - J Natl Cancer Inst VL - 17 UR - https://doi.org/10.1093/jnci/djg117 DO - 10.1093/jnci/djg117 ID - Lu2003 ER - TY - JOUR AU - Bundred, N. J. AU - Anderson, E. A. AU - Gee, J. AU - Barr, L. AU - Baildam, A. AU - Zeiton, A. AU - Byrne, G. AU - Grassby, S. AU - Nicholson, R. I. AU - Koehler, M. PY - 2003 DA - 2003// TI - Randomised, double-blind, placebo-controlled trial of short-term effects of gefitinib ('Iressa', ZD1839) on ductal carcinoma in situ [abstract 14] JO - Breast Cancer Res Treat VL - 82 ID - Bundred2003 ER -